Harlequin ichthyosis — designated HI, OMIM #242500, one of the most severe and life-threatening genetic skin disorders known to medicine, affecting approximately 1 in 300,000 to 500,000 live births worldwide with fewer than 200 individuals alive at any time globally, caused by biallelic loss-of-function mutations in the ABCA12 gene encoding ATP-binding cassette transporter A12, a lipid transporter essential for the formation of lamellar bodies in the epidermal granular layer and the delivery of lipids to the stratum corneum — resulting in a profoundly disrupted epidermal permeability barrier characterized at birth by the pathognomonic presentation of thick, armor-like plates of stratum corneum covering the entire body surface with deep fissures at skin folds, ectropion (eversion of the eyelids exposing the sclera), eclabium (eversion of the lips), ear canal occlusion, respiratory compromise from chest wall restriction, and limb constriction bands that can impair circulation; the immediate neonatal period represents the highest-mortality phase as infants are managed in the neonatal intensive care unit with thermoregulation support (the massive evaporative water loss through the disrupted barrier causes temperature instability), nutritional support, infection prevention (the fissured skin is a portal of entry for systemic sepsis), intensive topical emollient therapy to soften and shed the constricting ichthyotic plates, respiratory management for chest wall restriction, and ophthalmological management to protect the exposed corneas from desiccation injury; surviving the neonatal period, individuals with harlequin ichthyosis carry a lifetime of intensive dermatological management including multiple daily baths, continuous aggressive emollient application, retinoid therapy (acitretin, the retinoid that reduces the rate of keratinocyte proliferation and normalizes the differentiation program disrupted by ABCA12 loss-of-function, has transformed survival and quality of life for HI patients and is now considered standard of care for moderate-to-severe HI), ongoing ophthalmological management for persistent ectropion and corneal exposure, hearing management for ear canal obstruction, recurrent infection surveillance, and multidisciplinary coordination across dermatology, ophthalmology, otolaryngology, nutrition, infectious disease, and social support — with the ABCA12 mutation spectrum (truncating mutations, splice site mutations, missense mutations of the Walker A and B ATP-binding motifs) correlating imperfectly with phenotypic severity and retinoid responsiveness, and the molecular confirmation by ABCA12 sequencing providing both diagnostic certainty and reproductive genetic counseling for the autosomal recessive inheritance pattern.
Harlequin ichthyosis technology platforms — encompassing the neonatal intensive care and rare skin disease specialty clinical platforms where the pathognomonic newborn presentation triggers urgent ABCA12 molecular confirmation and the multidisciplinary neonatal stabilization protocol is deployed, the genetic testing platforms where ABCA12 biallelic variant identification confirms the diagnosis and enables carrier testing for parents and future reproductive planning, the dermatology specialty platforms coordinating the lifelong intensive skin care regimen including retinoid therapy, the ophthalmology platforms managing ectropion, corneal exposure, and chronic ocular surface disease, the otolaryngology platforms managing ear canal obstruction and hearing function, the nutrition and growth platforms monitoring the impact of evaporative water loss and metabolic demands on growth, the infectious disease platforms managing the recurrent skin and systemic infections arising from the disrupted barrier, the pharmacy platforms managing acitretin therapy including the mandatory pregnancy prevention program, and the rare disease patient registry and multidisciplinary coordination platforms supporting the global HI patient community — must maintain the availability and performance standards required by the neonatal life support urgency, the retinoid therapy monitoring obligations, the lifelong multidisciplinary coordination intensity, and the infection surveillance demands that define modern harlequin ichthyosis management. This guide explains why harlequin ichthyosis tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the neonatal emergency stabilization, ABCA12 genetic confirmation, retinoid therapy management, ophthalmological surveillance, and lifelong multidisciplinary coordination that define modern HI care.
Why Harlequin Ichthyosis Tech Platforms Require Specialized Monitoring Attention
Harlequin ichthyosis management is defined by several uniquely severe genetic disorder management challenges: the neonatal critical care emergency — newborns with harlequin ichthyosis require immediate NICU admission with isolation, thermoregulation support, humidified incubator management, topical emollient therapy (petroleum jelly or equivalent applied every 2–4 hours), nasogastric feeding for the eclabium that prevents effective oral feeding, ophthalmological intervention for ectropion and corneal protection, respiratory management for thoracic restriction, and the NICU-coordinated multidisciplinary team activation that must begin within hours of birth; the retinoid therapy management complexity — acitretin, the standard systemic retinoid for HI, requires teratogenicity counseling and mandatory pregnancy prevention program compliance (Category X teratogen with two forms of effective contraception required for females of childbearing potential and for 3 years after discontinuation), liver function monitoring, lipid monitoring, bone density surveillance for long-term use, and growth monitoring for pediatric patients, making the specialty pharmacy and dermatology coordination platforms critical infrastructure; the ophthalmological emergency vigilance — corneal exposure from ectropion creates continuous risk of corneal ulceration, scarring, and vision loss that requires ophthalmological monitoring platforms to coordinate artificial tear schedules, lubricating ointment application, moisture chamber spectacles, and ophthalmology follow-up escalation when corneal integrity is threatened; and the infection surveillance imperative — the disrupted stratum corneum is a portal of entry for Staphylococcus aureus, Pseudomonas aeruginosa, and invasive fungal infections that can cause life-threatening sepsis, requiring continuous skin infection monitoring and rapid infectious disease escalation.
ABCA12 molecular genetic testing platforms are the definitive diagnostic tool. Biallelic ABCA12 variants confirmed by sequencing — Sanger or next-generation sequencing — provide the molecular diagnosis of harlequin ichthyosis and enable autosomal recessive carrier testing for parents. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
Neonatal ICU coordination platforms must support 24/7 multidisciplinary HI management. The NICU platforms coordinating dermatology, ophthalmology, respiratory therapy, nutrition, and infectious disease management from the first hours of life must be available continuously. Monitor NICU coordination platforms at 1-minute intervals, 24/7.
Acitretin management platforms coordinate retinoid therapy and pregnancy prevention. The mandatory pregnancy prevention program — monthly negative pregnancy tests before dispensing, dual contraception documentation, teratogenicity counseling — alongside liver function, lipid, and bone density monitoring platforms require continuous availability during clinical and pharmacy hours. Monitor retinoid management platforms at 1-minute intervals during operational hours.
Ophthalmology platforms track corneal exposure and ectropion management. Serial slit-lamp examinations, corneal fluorescein staining, and artificial tear and ointment regimen adherence monitoring must be available without interruption. Monitor ophthalmology platforms at 1-minute intervals during clinical hours.
Infectious disease surveillance platforms monitor skin infection and sepsis risk. Wound culture platforms, antibiogram tracking, and infection escalation protocols require continuous availability. Monitor infectious disease platforms at 1-minute intervals during clinical hours.
What to Monitor on a Harlequin Ichthyosis Tech Platform
Genetic Testing — ABCA12 Biallelic Variant Confirmation
Monitor genetic testing referral records (clinical HI neonatal presentation documentation — pathognomonic armor-plate stratum corneum with ectropion and eclabium at birth, urgent molecular confirmation request, ABCA12 sequencing order, chromosomal microarray exclusion of alternative diagnoses), ABCA12 NGS and Sanger sequencing records (biallelic variant identification — truncating mutation, splice site mutation, or Walker A/B missense variant; zygosity confirmation; variant classification for each allele; pathogenicity assessment), parental carrier testing records (autosomal recessive inheritance — identification of heterozygous carrier status in each parent), preimplantation genetic testing coordination records for future pregnancies, and genetic counseling records (reproductive implications, 25% recurrence risk for subsequent pregnancies, prenatal diagnosis options) at 1-minute intervals during laboratory hours. Alert immediately — ABCA12 molecular testing platform failures during the diagnostic evaluation of a neonate admitted to the NICU with the pathognomonic harlequin ichthyosis presentation delay molecular confirmation that informs prognosis communication to the family, guides retinoid therapy initiation timing, and enables carrier testing for parents planning future reproductive decisions.
Neonatal ICU — Stabilization and Multidisciplinary Management
Monitor neonatal admission and isolation records (NICU isolation protocols, humidified incubator setup, temperature and humidity monitoring, evaporative water loss calculation), topical emollient therapy records (petroleum jelly or equivalent application schedule documentation — every 2–4 hours for newborns, product rotation to prevent sensitization, application technique instructions for nursing staff), nasogastric feeding records (caloric intake documentation, growth velocity monitoring, transition to oral feeding assessment as eclabium resolves with emollient therapy and first skin shedding), ophthalmological intervention records (ectropion management — lubricating eye drops and ointment schedule, moisture chamber or protective eyewear, ophthalmology consultation timing), respiratory management records (chest wall excursion assessment, oxygen supplementation, respiratory therapy coordination for thoracic restriction), and neonatal pain management records (emollient application in fissured skin is painful — pain scoring, analgesic administration, developmental care interventions) at 1-minute intervals, 24/7. Alert immediately — NICU coordination platform failures during the first 72 hours of life for a harlequin ichthyosis neonate — the period of highest mortality risk from sepsis, thermoregulatory failure, and respiratory restriction — leave nursing, dermatology, ophthalmology, respiratory therapy, and nutrition teams without the coordination infrastructure that synchronizes the multiple simultaneous intensive interventions required.
Dermatology — Lifelong Skin Care Regimen and Retinoid Therapy
Monitor dermatology outpatient coordination records (follow-up scheduling for acitretin-treated patients — baseline and interval skin assessments, SCORAD-equivalent HI severity scoring, acitretin dose adjustment records based on clinical response and tolerability), acitretin prescription and dispensing records (dose in mg/kg/day for pediatric patients, dose in adults, brand and generic availability confirmation, specialty pharmacy coordination), skin care regimen documentation records (daily emollient protocol — bath frequency and duration, emollient type and quantity, application technique, scale debridement approach, scalp care, nail management), and acitretin adverse effect monitoring records (dry lips and mucous membranes, hair thinning, arthralgias — patient-reported adverse effects guiding dose adjustment) at 1-minute intervals during clinical hours. Alert immediately — dermatology platform failures that prevent the access to a 14-year-old HI patient's current acitretin dose, liver function trajectory, and skin care regimen during an urgent visit for a skin infection exacerbation leave the dermatologist without the medication history needed to manage the infection in the context of the ongoing systemic retinoid therapy.
Acitretin Pregnancy Prevention Program
Monitor mandatory pregnancy testing records (monthly urine pregnancy test before each acitretin refill for female patients of childbearing potential, pregnancy test result to dispensing gate linkage, test result date and result value), dual contraception counseling records (documentation that the patient understands and is using two effective forms of contraception simultaneously, contraceptive method documentation, annual re-counseling attestation), teratogenicity counseling records (counseling that acitretin converts in vivo to etretinate which is stored in adipose tissue and remains teratogenic for at least 3 years after discontinuation — the 3-year contraception obligation post-discontinuation must be documented and understood), and post-discontinuation monitoring records (contraception documentation for 36 months after last acitretin dose, pregnancy test at 1-month, 6-month, 12-month, and annually after discontinuation) at 1-minute intervals during clinical and pharmacy hours. Alert immediately — acitretin pregnancy prevention program platform failures prevent the monthly pregnancy test result linkage that is the regulatory-required gate before each dispensing for a 19-year-old female HI patient.
Ophthalmology — Ectropion and Corneal Exposure Surveillance
Monitor slit-lamp examination records (corneal fluorescein staining for epithelial defects, corneal clarity assessment, ectropion severity grading, conjunctival injection and discharge documentation), artificial tear and lubricating ointment adherence records (scheduled lubricant application documentation, patient-reported adherence, adverse effects of specific products), moisture chamber spectacle and protective eyewear records (prescription and fitting, adherence documentation, lens and moisture chamber replacement scheduling), and corneal ulceration escalation records (emergency ophthalmology consultation triggers, corneal ulcer identification, antibiotic and antifungal therapy, bandage contact lens and amniotic membrane transplant utilization for severe corneal surface disease) at 1-minute intervals during clinical hours. Alert immediately — ophthalmology platform failures that prevent an HI care team from accessing a 10-year-old patient's current artificial tear schedule, most recent slit-lamp findings, and ectropion severity grading during an urgent visit for a red and painful eye leave the ophthalmologist without the baseline documentation needed to identify interval changes in corneal integrity.
Infectious Disease — Skin Infection and Sepsis Surveillance
Monitor wound culture and microbiology records (skin swab culture results — Staphylococcus aureus including MRSA, Pseudomonas aeruginosa, beta-hemolytic Streptococcus, Candida species; antibiogram documentation; culture-to-antibiotic selection linkage), systemic infection surveillance records (fever alerts, CBC with differential tracking, blood culture results, procalcitonin for bacterial sepsis monitoring), antibiotic therapy records (topical antibiotic use, systemic antibiotic prescription, duration, de-escalation based on culture results), and infection escalation protocol records (triggers for infectious disease consultation, sepsis protocol activation for HI patients with fever or clinical deterioration, dermatology-infectious disease co-management communication records) at 1-minute intervals during clinical hours. Alert immediately — infectious disease platform failures that delay antibiogram review for an 8-year-old HI patient with a rapidly expanding skin infection and fever prevent the timely antibiotic de-escalation or escalation that distinguishes local skin infection from early sepsis in a patient whose disrupted epidermal barrier creates continuous bacteremia risk.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Harlequin ichthyosis management coordinates across neonatal intensive care (NICU stabilization), genetics and rare disease (ABCA12 diagnosis), dermatology (skin care and acitretin management), ophthalmology (ectropion and corneal management), otolaryngology (ear canal and hearing management), nutrition (growth and metabolic support), infectious disease (sepsis prevention and treatment), pharmacy and specialty pharmacy (acitretin pregnancy prevention program), and rare disease patient coordination — authentication failures block every team member required to execute the lifelong intensive multidisciplinary management that defines HI care.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, NICU coordination portals, dermatology and retinoid management systems, ophthalmology tracking platforms, infectious disease surveillance systems, and rare disease coordination platforms. Certificate errors disrupt neonatal emergency coordination, acitretin pregnancy prevention program compliance, and ophthalmological escalation workflows.
HIPAA and Ultra-Rare Disease Patient Privacy Considerations
Harlequin ichthyosis technology platforms handle highly sensitive PHI for a patient population so small (fewer than 200 individuals alive globally at any time) that individual patient identification risk is substantial even with standard de-identification — a 15-year-old with HI in virtually any metropolitan area may be one of very few such patients in the country, making diagnosis-linked data re-identification risk near-certain without exceptional de-identification rigor. Records include ABCA12 biallelic molecular genetic testing with autosomal recessive inheritance implications for parents and siblings, mandatory pregnancy prevention program testing including monthly pregnancy test results and contraceptive method documentation, NICU admission records from birth, a lifetime of dermatology records documenting the visible body surface condition, ophthalmological records, and rare disease registry enrollment.
The heritable nature of ABCA12 mutations creates genetic information privacy obligations under GINA (Genetic Information Nondiscrimination Act) in addition to HIPAA Privacy and Security Rule requirements. For neonatal critical care platforms managing newborns with harlequin ichthyosis — where platform unavailability during the highest-mortality neonatal period has direct patient safety implications — availability monitoring provides operational documentation relevant to both HIPAA Security Rule and neonatal patient safety compliance frameworks.
Alerting Strategy for Harlequin Ichthyosis Tech Platforms
Immediate 24/7 alerting for NICU coordination platforms: Harlequin ichthyosis neonatal management requires continuous multidisciplinary coordination during the highest-mortality period. NICU platform availability has no acceptable window of disruption.
Immediate laboratory-hours alerting for genetic testing platforms: ABCA12 biallelic sequencing — Sanger and NGS panel. These must be available during the molecular confirmation that informs prognosis, retinoid therapy initiation, and parental carrier counseling.
Immediate clinical-hours alerting for dermatology and retinoid management platforms: Acitretin pregnancy prevention program, liver function monitoring, lipid monitoring, bone density surveillance, and skin care regimen coordination cannot fail during clinical hours.
Immediate clinical-hours alerting for ophthalmology platforms: Corneal exposure from ectropion creates continuous vision-threatening risk that requires ophthalmological monitoring platforms without interruption during clinical hours.
Immediate clinical-hours alerting for infectious disease surveillance platforms: Skin culture, antibiogram, and sepsis escalation platforms for a patient population with a persistently disrupted epidermal barrier.
Sustained-failure alert (10–15 minutes): Rare disease patient registry, patient support community platforms, and long-term growth and metabolic monitoring.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms HI platform availability from the geographies where harlequin ichthyosis specialty centers, ABCA12 molecular genetic testing programs, and acitretin specialty pharmacy networks concentrate.
Status Page for Harlequin Ichthyosis Care Team Communication
A real-time status page gives NICU directors managing harlequin ichthyosis neonates, dermatologists coordinating lifelong acitretin and skin care regimens, ophthalmologists monitoring corneal exposure and ectropion severity, genetic counselors communicating ABCA12 results and reproductive implications, specialty pharmacists managing acitretin pregnancy prevention program compliance, infectious disease specialists managing skin and systemic infections, and rare disease coordinators managing registry enrollment and family support immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in NICU harlequin ichthyosis management protocols, acitretin dispensing procedures, and ophthalmological escalation workflows.
Vigilmon Setup for Harlequin Ichthyosis Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | NICU coordination (multidisciplinary HI management) | 1 min | Slack + PagerDuty (24/7) | | ABCA12 biallelic molecular testing (Sanger / NGS) | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and carrier testing | 1 min | Slack + PagerDuty (lab hours) | | Acitretin prescription and dispensing | 1 min | Slack + PagerDuty (clinical hours) | | Acitretin pregnancy prevention program (monthly pregnancy test gate) | 1 min | Slack + PagerDuty (clinical hours) | | Liver function and lipid monitoring (acitretin) | 1 min | Slack + PagerDuty (lab hours) | | Bone density surveillance (long-term acitretin) | 2 min | Slack + PagerDuty (clinical hours) | | Dermatology skin care regimen coordination | 1 min | Slack + PagerDuty (clinical hours) | | Ophthalmology — slit-lamp and corneal exposure | 1 min | Slack + PagerDuty (clinical hours) | | Corneal ulceration escalation protocol | 1 min | Slack + PagerDuty (24/7) | | Wound culture and antibiogram | 1 min | Slack + PagerDuty (clinical hours) | | Systemic infection surveillance (CBC, blood culture, procalcitonin) | 1 min | Slack + PagerDuty (clinical hours) | | Ear canal and hearing management (ORL) | 2 min | Slack + PagerDuty (clinical hours) | | Nutrition and growth monitoring | 2 min | Slack (business hours) | | Rare disease patient registry | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure NICU coordination platform with 24/7 immediate alerting — this is the highest-priority platform during the neonatal period
- Add ABCA12 biallelic molecular testing platforms with immediate laboratory-hours alerting
- Configure genetic counseling and carrier testing platforms with immediate laboratory-hours alerting
- Add acitretin prescription and dispensing platforms with immediate clinical-hours alerting
- Configure acitretin pregnancy prevention program (monthly pregnancy test gate) with immediate clinical-hours alerting
- Add liver function and lipid monitoring platforms with immediate laboratory-hours alerting
- Configure bone density surveillance platforms with sustained-failure alerting during clinical hours
- Add dermatology skin care regimen coordination platforms with immediate clinical-hours alerting
- Configure ophthalmology slit-lamp and corneal exposure monitoring platforms with immediate clinical-hours alerting
- Add corneal ulceration escalation protocol with 24/7 immediate alerting
- Configure wound culture and antibiogram platforms with immediate clinical-hours alerting
- Add systemic infection surveillance platforms with immediate clinical-hours alerting
- Configure otolaryngology ear canal and hearing management platforms with sustained-failure alerting
- Add nutrition and growth monitoring platforms with sustained-failure alerting during business hours
- Configure rare disease patient registry with sustained-failure alerting
- Enable SSL certificate monitoring across all genetic testing, NICU, dermatology, ophthalmology, pharmacy, and registry platforms
- Add the status page URL to NICU harlequin ichthyosis management protocols, acitretin pregnancy prevention program documentation, and ophthalmological escalation guidelines
Conclusion
Harlequin ichthyosis technology platforms are embedded in clinical decisions where NICU coordination platform availability at any hour of the day or night — when a neonatal team is managing the first 48 hours of life for a harlequin ichthyosis neonate who must receive topical emollient every 2–4 hours, has ectropion requiring lubricating eye drops every hour, is being nasogastrically fed because the eclabium prevents effective oral intake, is in a humidified incubator because the massive evaporative water loss through the disrupted stratum corneum causes dangerous hypothermia without environmental humidity supplementation, and whose fissured skin creates an imminent portal of entry for the Staphylococcus aureus and Pseudomonas aeruginosa that cause the sepsis that is one of the leading causes of harlequin ichthyosis neonatal mortality — cannot be disrupted by NICU coordination platform failures that leave the nursing, dermatology, ophthalmology, nutrition, and infectious disease teams without the synchronized multidisciplinary management infrastructure that keeps this neonate alive through the most dangerous period of a dangerous disease; where ABCA12 molecular testing platform availability during the first days of life — when the genetic confirmation of biallelic ABCA12 mutations provides the diagnostic certainty that allows the family to be counseled about their child's diagnosis, prognosis, and the treatment trajectory from the neonatal intensive emollient regimen to the lifelong acitretin therapy that has transformed HI survivorship — cannot be disrupted by testing platform failures that delay the molecular result while the family is in the most acute phase of processing their newborn's diagnosis; where acitretin pregnancy prevention program platform availability for a 20-year-old female HI patient — when the specialty pharmacy must confirm that this month's urine pregnancy test is negative and that the patient has documented dual contraception before dispensing the next 30-day supply of the Category X teratogen that controls her skin disease — cannot be disrupted by specialty pharmacy platform failures that prevent the pregnancy test result to dispensing linkage that is both a regulatory requirement and an ethical obligation protecting this patient from an acitretin-related teratogenic pregnancy; and where ophthalmological escalation platform availability for a 12-year-old HI patient presenting with a red, painful, photophobic eye — when the ophthalmologist needs the patient's current artificial tear schedule, last slit-lamp examination findings, and ectropion severity grading to determine whether this represents a corneal epithelial defect that can be managed with intensive lubrication and a bandage contact lens, or a corneal ulcer that requires immediate antibiotic or antifungal therapy and emergency ophthalmology management to prevent the corneal scarring that could cause permanent visual impairment in a child already carrying the extraordinary burden of harlequin ichthyosis — cannot be disrupted by ophthalmological platform failures that leave the care team without the baseline documentation needed to triage the most vision-threatening emergency in HI care. A NICU coordination platform unavailable when a neonatal team is fighting to keep a harlequin ichthyosis newborn alive, an ABCA12 molecular testing platform interrupted when genetic confirmation must be delivered to a family in the most acute period of their child's life, an acitretin pregnancy prevention program platform failing when the monthly dispensing gate must be executed for a patient on a Category X teratogen, an ophthalmological platform unavailable when a corneal ulcer in an HI patient must be triaged — these are not IT incidents. They are clinical disruptions in the management of one of the rarest and most severe genetic skin disorders in medicine, whose neonatal critical care urgency, lifelong retinoid therapy management, continuous corneal exposure surveillance, and persistent infection risk make NICU coordination platform 24/7 availability, ABCA12 molecular testing continuity, acitretin pregnancy prevention program platform reliability, and ophthalmological escalation platform availability the operational foundations on which harlequin ichthyosis survivorship depends.
Uptime monitoring gives harlequin ichthyosis tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to NICU directors, dermatology specialty centers, ophthalmology programs, specialty pharmacies, and compliance auditors that platform operational reliability matches the neonatal emergency coordination precision, genetic diagnostic requirements, retinoid therapy management obligations, and continuous corneal surveillance intensity of modern HI care.
Start monitoring your harlequin ichthyosis care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #harlequin #ichthyosis #ABCA12 #lipid #transporter #neonatal #NICU #acitretin #retinoid #pregnancy #prevention #ectropion #eclabium #stratum #corneum #rare #genetic #skin #disorder #HIPAA #healthtech #digitalhealth #uptime #sre